Abstract: Following cutting of a develop-on-press printing member, a treatment fluid having a pH greater than 6 is applied to one or both edges prior to its development and use in order to avoid ink lines during printing.

Abstract: The blanket cylinder of a printing press is used to remove oleophobic debris from an imaged dry printing member. Following imaging—e.g., imagewise exposure of the printing member to radiation that ablates the layer below the oleophobic layer, or de-anchors it from the oleophobic layer without ablation—the printing member is brought into rolling contact with the blanket cylinder, and the press is operated “on impression.” This rolling contact may remove not only the oleophobic top layer but ablation debris of the underlying imaging layer as well.

Abstract: The blanket cylinder of a printing press is used to remove oleophobic debris from an imaged dry printing member. Following imaging—e.g., imagewise exposure of the printing member to radiation that ablates the layer below the oleophobic layer, or de-anchors it from the oleophobic layer without ablation—the printing member is brought into rolling contact with the blanket cylinder, and the press is operated “on impression.” This rolling contact may remove not only the oleophobic top layer but ablation debris of the underlying imaging layer as well.

Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgG1 proteins; (c) having kappa light chains; (d) being Glm(3) or Glm(1,17) allotype; (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibodies of cell lines ECACC 87091605 and 87091604 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England on Sep. 16, 1987.

Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgG3 proteins; (c) having kappa light chains; (d) being of the allotype G3m(21); (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibody of cell line ECACC 87091606 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England, on Sep. 16, 1987.

Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgG3 proteins; (c) having kappa light chains; (d) being of the allotype G3m(21); (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibody of cell line ECACC 87091606 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England of Sep. 16, 1987.

Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgGl proteins; (c) having kappa light chains; (d) being Glm(3) or Glm(1,17) allotype; (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibodies of cell lines ECACC 87091605 and 87091604 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England on 16th September 1987.